Lisaftoclax - CISMeF

Preferred Label : Lisaftoclax;

NCIt synonyms : Bcl-2 Inhibitor APG 2575;

NCIt definition : An orally bioavailable and selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, lisaftoclax targets, binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.;

UNII : OSL3FEZ1IF;

CAS number : 2180923-05-9;

Molecule name : APG-2575; APG 2575;

NCI Metathesaurus CUI : CL562961;

Détails

Origin ID

C156249;

UMLS CUI

C5667172;

Currated CISMeF NLP mapping
- Lisaftoclax [MeSH Supplementary Concept]
- Lisaftoclax [MeSH concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Lisaftoclax [MeSH Supplementary Concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Apoptosis Regulator Bcl-2 [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients